Remimazolam: First Approval

被引：0
作者：
Susan J. Keam
机构：
[1] Springer Nature,
来源：
Drugs | 2020年 / 80卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Remimazolam (Anerem® in Japan; ByFavo™ in the USA; Aptimyda™ in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation. Remimazolam was approved on 23 January 2020 in Japan for use in general anesthesia in adult patients. Remimazolam is also undergoing regulatory assessment in South Korea for this indication and for use in procedural sedation in the USA, the EU and China. This article summarises the major milestones in the development of remimazolam for this first approval for the induction and maintenance of general anaesthesia, and its potential upcoming approvals in general anaesthesia and procedural sedation.
引用
收藏
页码：625 / 633
页数：8
相关论文
共 47 条
  • [1] Wesolowski AM(2016)Remimazolam: pharmacologic considerations and clinical role in anesthesiology Pharmacotherapy 36 1021-1027
  • [2] Zaccagnino MP(2016)New horizons for sedation: the ultrashort acting benzodiazepine remimazolam Tech Gastrointest Endosc 18 22-28
  • [3] Malapero RJ(2007)CNS 7056: a novel ultra-short-acting benzodiazepine Anesthesiology 107 60-66
  • [4] Pambianco DJ(2017)Inhaled remimazolam potentiates inhaled remifentanil in rodents Anesth Analg 124 1484-1490
  • [5] Cash BD(2012)A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part II—population pharmacokinetic and pharmacodynamic modeling and simulation Anesth Analg 115 284-296
  • [6] Kilpatrick GJ(2012)A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I—safety, efficacy, and basic pharmacokinetics Anesth Analg 115 274-283
  • [7] McIntyre MS(2020)Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers Eur J Clin Pharmacol 76 383-391
  • [8] Cox RF(2020)Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I—pharmacokinetics and clinical pharmacodynamics Anesthesiology 132 636-651
  • [9] Bevans T(2020)Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part II—pharmacodynamics of electroencephalogram effects Anesthesiology 132 652-666
  • [10] Deering-Rice C(2020)Time-to-event modeling for remimazolam for the indication of induction and maintenance of general anesthesia J Clin Pharmacol 117 1093-1100
12345